Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- October15 2004
- Volume 11
- Issue 19
Vote Counting
Advertisement
29%—Percentage of Americans under age 25 who voted in the 2000 US presidential election.
63%—Percentage of Americans over age 55 who voted in the 2000 US presidential election.
36%—Percentage of Americans whose annual income was less than $17,000who voted in the 2000 US presidential election.
66%—Percentage of Americans whose annual income was greater than$55,000 who voted in the 2000 US presidential election.
(New York Times, 2004)
Articles in this issue
about 18 years ago
Question Your Ideal Investment Optionabout 18 years ago
Determine when a Roth IRA Makes Senseabout 18 years ago
Ponder the Privatized Social Security Issueabout 18 years ago
Accelerate Retirement Savings with a 412(i)about 18 years ago
Replace Malpractice Fiction with Factabout 18 years ago
Expand Your Insurance Protection Planabout 18 years ago
Save More with College Rewards Programsabout 18 years ago
Select a Team Worthy of the Super Bowlabout 18 years ago
Recover Taxes from a Natural Disasterabout 18 years ago
Strengthen Your Retirement with CharityAdvertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care
5